ArticleCureus2025
Antineutrophil Cytoplasmic Antibodies-Associated Glomerulonephritis in Diabetic Kidney Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease is a very prevalent complication in the context of type 2 diabetes. However, there is evidence showing a high variability in diagnosis when a kidney biopsy is performed. We present a case of a woman with a diagnosis of diabetic kidney disease, systemic arterial hypertension, obesity, and a high risk of progression of chronic kidney disease who presented with a sudden onset nephrotic syndrome and rapidly progressive deterioration of renal function. Kidney biopsy revealed pauci-immune extracapillary glomerulonephritis with acute thrombotic microangiopathy and class IIa diabetic nephropathy. Antineutrophil cytoplasmic antibodies (ANCA) and low complement were detected. The patient received treatment based on plasma exchanges, steroids with methylprednisolone and prednisone and intravenous cyclophosphamide with improvement of renal function. In conclusion, expansion of kidney biopsy criteria in patients with a diagnosis of type 2 diabetes is mandatory to provide adequate treatment and prognosis in the context of a high prevalence of alternative or concomitant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.